Radnostix, Inc. Share Price

INIS

US45972C1027

Pharmaceuticals

Market Closed - OTC Markets 15:30:58 02/06/2026 BST			5-day change	1st Jan Change
0.0711 ^USD	-15.16%		+9.05%	+16.08%

08-12	Radnostix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-24	Radnostix, Inc. acquired Certain Assets of Lucerno Dynamics, LLC for 1.65 million.	CI

Analysts' recommendations: Radnostix, Inc.

17/10/25

International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025

More recommendations

Press Releases: Radnostix, Inc.

08-13	Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition	PR
08-13	Radnostix : Reports FY2026 2nd Quarter and Six Months Results – Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition	PU
07-02	Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio	PR
05-21	Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown	PR
04-01	Radnostix, Inc. Reports FY2025 Results - Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025	PR

More press releases

Managers and Directors: Radnostix, Inc.

Manager	Title	Age	Since
Shahe Bagerdjian CEO	Chief Executive Officer	42	31/08/2023
W. Cox DFI	Director of Finance/CFO	42	29/09/2019
John Miller LAW	General Counsel	61	31/12/2000

Director	Title	Age	Since
Steve Laflin BRD	Director/Board Member	69	31/05/2001
Christopher Grosso CHM	Chairman	58	30/06/2017
Robert Atcher BRD	Director/Board Member	74	01/08/2017

More insiders

Diagnostic & Testing Substances Manufacturers

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RADNOSTIX, INC.	-15.16%	+9.05%	+18.50%	+41.07%	33.6M
SAREPTA THERAPEUTICS, INC.	+3.33%	+0.43%	+11.58%	-82.65%	2.2B
ULTRAGENYX PHARMACEUTICAL INC.	+6.59%	+19.47%	-47.01%	-57.14%	1.53B
BIONOTE, INC.	+0.43%	-1.27%	-23.19%	-2.30%	347M
DK LIFE SCIENCE CO., LTD.	+29.98%	+34.29%	-30.15%	-	71.52M
Average	+5.03%	+10.09%	-14.05%	-25.25%	837.05M
Weighted average by Cap.	+4.59%	+7.83%	-13.45%	-65.34%

See all sector performances

Radnostix, Inc. is a manufacturer of radioisotope-focused products for medical, industrial, and research applications. The Company's segments include Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. Theranostics Products segment produces an FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and thyroid cancer; radiochemicals for multiple uses in clinical research and life sciences, and cGMP API supply for third party theranostics clients. Cobalt Products segment produces a variety of cobalt-60 products. Medical Devices segment sells various third-party products and is developing its own products for commercial use. Calibration & Reference Products segment manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under the Company's RadQual brand.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
21/09/26	US$0.0635	+5.66%	400
18/09/26	US$0.0601	+0.17%	33,900
17/09/26	US$0.0600	-.--%	4,190
16/09/26	US$0.0600	-7.98%	16,257
15/09/26	US$0.0652	+5.16%	10,688

Real-time OTC Markets

More quotes

Market Cap	33.6M 29.36M 27.6M 25.19M 47.27M 3.21B 47.28M 331M 128M 1.64B 126M 123M 5.29B	P/E 2024	2,150x	P/E 2025	-35.5x
Enterprise Value	40.81M 35.66M 33.52M 30.59M 57.4M 3.9B 57.42M 402M 155M 1.99B 153M 150M 6.42B	EV / Sales 2024	1.76x	EV / Sales 2025	3.03x
Free-Float	26.54%	Yield 2024 *	-	Yield 2025	-

08-12	Radnostix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-24	Radnostix, Inc. acquired Certain Assets of Lucerno Dynamics, LLC for 1.65 million.	CI
05-20	Radnostix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-03	Radnostix Inc Voluntary Recalls Gelatin Capsule Pack for Use with the Sodium Iodide I-131 Kit	CI
03-31	Radnostix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	International Isotopes Inc Withdraws Request on Behalf of International Isotopes Fluorine Products and Green Salt Products, LLC for Nuclear Regulatory Commission Consent for Direct License Transfer	CI
12-31	International Isotopes Inc. has Changed its Name to Radnostix, Inc	CI
11-14	International Isotopes Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
17/10/25	International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025	CI
13/08/25	International Isotopes Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/05/25	International Isotopes Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
04/03/25	International Isotopes Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
04/03/25	International Isotopes Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI

1 day	-15.16%
1 week	+9.05%
Current month	+18.50%
1 month	+6.44%
3 months	+1.57%
6 months	-17.13%
Current year	+16.08%

1 week	0.06	0.08
1 month	0.05	0.08
Current year	0.05	0.1
1 year	0.05	0.11
3 years	0.02	0.11
5 years	0.02	0.11
10 years	0	0.34

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/10/25	Robert Atcher	Free	Director	250,000	0.0478%
10/10/25	Christopher Grosso	Free	Chairman	500,000	0.0955%
10/10/25	Steve Laflin	Free	Director	500,000	0.0955%

Radnostix, Inc. Share Price

Stocks

INIS

US45972C1027

Pharmaceuticals

Valuation: Radnostix, Inc.

Chart: Radnostix, Inc.

Latest news: Radnostix, Inc.

Analysts' recommendations: Radnostix, Inc.

Press Releases: Radnostix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Radnostix, Inc.

Latest insider transactions

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile

Quotes

	2024	2025
Net sales	13.9M 12.15M 11.42M 10.42M 19.55M 1.33B 19.56M 137M 52.87M 679M 52.2M 51.06M 2.19B	13.07M 11.42M 10.74M 9.8M 18.39M 1.25B 18.39M 129M 49.72M 638M 49.08M 48.01M 2.06B
Net income	8.57K 7.49K 7.04K 6.43K 12.06K 820K 12.06K 84.52K 32.61K 419K 32.2K 31.49K 1.35M	-908K -794K -746K -681K -1.28M -86.8M -1.28M -8.95M -3.45M -44.33M -3.41M -3.34M -143M
Net Debt	6.42M 5.61M 5.27M 4.81M 9.03M 613M 9.03M 63.25M 24.41M 313M 24.1M 23.57M 1.01B	7.21M 6.3M 5.92M 5.4M 10.14M 689M 10.14M 71.03M 27.41M 352M 27.06M 26.47M 1.13B